These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
280 related articles for article (PubMed ID: 2402791)
21. Acute graft-versus-host disease prophylaxis with methotrexate and cyclosporine after busulfan and cyclophosphamide in patients with hematologic malignancies. von Bueltzingsloewen A; Belanger R; Perreault C; Bonny Y; Roy DC; Lalonde Y; Boileau J; Kassis J; Lavallee R; Lacombe M Blood; 1993 Feb; 81(3):849-55. PubMed ID: 8427977 [TBL] [Abstract][Full Text] [Related]
22. A comparative trial of posttransplant immunosuppression in patients transplanted for thalassemia. Cyclosporine alone versus cyclosporine, cyclophosphamide, and methotrexate. Galimberti M; Polchi P; Lucarelli G; Giardini C; Baronciani D; Angelucci E; Politi P Transplantation; 1988 Mar; 45(3):566-9. PubMed ID: 3279581 [TBL] [Abstract][Full Text] [Related]
23. [Study on graft-versus-host disease in the allogeneic peripheral blood stem cell transplantation for the treatment of leukemia]. Zhang WP; Wang JM; Ju XP; Song XM; Tong SP; Li HM Zhonghua Xue Ye Xue Za Zhi; 2003 Mar; 24(3):129-33. PubMed ID: 12697123 [TBL] [Abstract][Full Text] [Related]
24. [Combination of mycophenolate mofetil with cyclosporine A and methotrexate as acute GVHD prophylaxis after unrelated donor allogeneic bone marrow transplantation]. Huang H; Lin M; Meng H; Qian W; Jin J; Huang J; Luo Y Zhonghua Xue Ye Xue Za Zhi; 2001 Feb; 22(2):76-8. PubMed ID: 11877053 [TBL] [Abstract][Full Text] [Related]
25. Cyclosporin A and mini short-term methotrexate vs cyclosporin A as graft-versus-host disease prophylaxis in patients with beta thalassemia major undergoing allogeneic blood and marrow transplantation. Iravani M; Mousavi A; Gholibeikian S; Bahar B; Samiee S; Ashouri A; Eghbal L; Ghavamzadeh A Bone Marrow Transplant; 2005 Jun; 35(11):1095-9. PubMed ID: 15821773 [TBL] [Abstract][Full Text] [Related]
26. Cyclosporine combined with methylprednisolone or methotrexate in prophylaxis of moderate to severe acute graft-versus-host disease. Gondo H; Harada M; Taniguchi S; Akashi K; Hayashi S; Teshima T; Takamatsu Y; Eto T; Nagafuji K; Yamasaki K Bone Marrow Transplant; 1993 Nov; 12(5):437-41. PubMed ID: 8298553 [TBL] [Abstract][Full Text] [Related]
27. Adjusted-dose continuous-infusion cyclosporin A to prevent graft-versus-host disease following allogeneic bone marrow transplantation. Miller KB; Schenkein DP; Comenzo R; Erban JK; Fogaren T; Hirsch CA; Berkman E; Rabson A Ann Hematol; 1994 Jan; 68(1):15-20. PubMed ID: 8110873 [TBL] [Abstract][Full Text] [Related]
28. FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors. Nash RA; Piñeiro LA; Storb R; Deeg HJ; Fitzsimmons WE; Furlong T; Hansen JA; Gooley T; Maher RM; Martin P; McSweeney PA; Sullivan KM; Anasetti C; Fay JW Blood; 1996 Nov; 88(9):3634-41. PubMed ID: 8896434 [TBL] [Abstract][Full Text] [Related]
29. HLA-identical sibling donor bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: influence of GVHD prophylaxis on outcome. Marks DI; Hughes TP; Szydlo R; Kelly S; Cullis JO; Schwarer AP; Mackinnon S; Apperley J; Barrett AJ; Hows JM Br J Haematol; 1992 Jul; 81(3):383-90. PubMed ID: 1390211 [TBL] [Abstract][Full Text] [Related]
30. [CD25 monoclonal antibody for GVHD prophylaxis in non-T-cell depleted haploidentical bone marrow transplantation for treatment of childhood leukemia]. Chen HR; Ji SQ; Yan HM; Wang HX; Liu J; Xue M; Zhu L Zhonghua Er Ke Za Zhi; 2004 Apr; 42(4):294-8. PubMed ID: 15157394 [TBL] [Abstract][Full Text] [Related]
31. Prophylaxis of graft-versus-host disease in identical sibling donor bone marrow transplant by anti-IL-2 receptor monoclonal antibody LO-Tact-1. Ferrant A; Latinne D; Bazin H; Straetmans N; Cornet A; de la Parra B; Michaux JL Bone Marrow Transplant; 1995 Oct; 16(4):577-81. PubMed ID: 8528175 [TBL] [Abstract][Full Text] [Related]
32. Do corticosteroids add any benefit to standard GVHD prophylaxis in allogeneic BMT? Ancín I; Ferrá C; Gallardo D; Peris J; Berlanga J; Gonzalez JR; Virgili N; Grañena A Bone Marrow Transplant; 2001 Jul; 28(1):39-45. PubMed ID: 11498742 [TBL] [Abstract][Full Text] [Related]
33. Cyclosporine monitoring improves graft-versus-host disease prophylaxis after bone marrow transplantation. Ghalie R; Fitzsimmons WE; Weinstein A; Manson S; Kaizer H Ann Pharmacother; 1994 Mar; 28(3):379-83. PubMed ID: 8193430 [TBL] [Abstract][Full Text] [Related]
34. De novo chronic graft-versus-host disease in marrow graft recipients given methotrexate and cyclosporine: risk factors and survival. Wagner JL; Seidel K; Boeckh M; Storb R Biol Blood Marrow Transplant; 2000; 6(6):633-9. PubMed ID: 11128814 [TBL] [Abstract][Full Text] [Related]
35. Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia. Pichert G; Roy DC; Gonin R; Alyea EP; Bélanger R; Gyger M; Perreault C; Bonny Y; Lerra I; Murray C J Clin Oncol; 1995 Jul; 13(7):1704-13. PubMed ID: 7602361 [TBL] [Abstract][Full Text] [Related]
36. Conditioning-related toxicity and acute graft-versus-host disease in patients given methotrexate/cyclosporine prophylaxis. Deeg HJ; Spitzer TR; Cottler-Fox M; Cahill R; Pickle LW Bone Marrow Transplant; 1991 Mar; 7(3):193-8. PubMed ID: 2059756 [TBL] [Abstract][Full Text] [Related]
37. Cyclosporin, methotrexate and prednisolone for graft-versus-host disease prophylaxis in allogeneic peripheral blood progenitor cell transplants. Hoyt R; Ritchie DS; Roberts AW; Macgregor L; Curtis DJ; Szer J; Grigg AP Bone Marrow Transplant; 2008 Apr; 41(7):651-8. PubMed ID: 18176619 [TBL] [Abstract][Full Text] [Related]
38. Cyclosporine in combination with mycophenolate mofetil versus methotrexate for graft versus host disease prevention in myeloablative HLA-identical sibling donor allogeneic hematopoietic cell transplantation. Hamilton BK; Rybicki L; Dean R; Majhail NS; Haddad H; Abounader D; Hanna R; Sobecks R; Duong H; Hill BT; Copelan E; Bolwell B; Kalaycio M Am J Hematol; 2015 Feb; 90(2):144-8. PubMed ID: 25353395 [TBL] [Abstract][Full Text] [Related]
39. Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Storb R; Deeg HJ; Farewell V; Doney K; Appelbaum F; Beatty P; Bensinger W; Buckner CD; Clift R; Hansen J Blood; 1986 Jul; 68(1):119-25. PubMed ID: 3521761 [TBL] [Abstract][Full Text] [Related]
40. Tacrolimus/Methotrexate versus cyclosporine/methotrexate as graft-versus-host disease prophylaxis in patients with severe aplastic anemia who received bone marrow transplantation from unrelated donors: results of matched pair analysis. Yagasaki H; Kojima S; Yabe H; Kato K; Kigasawa H; Sakamaki H; Tsuchida M; Kato S; Kawase T; Muramatsu H; Morishima Y; Kodera Y Biol Blood Marrow Transplant; 2009 Dec; 15(12):1603-8. PubMed ID: 19896085 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]